- Home
- EYE vs PSTX Comparison
EYE vs PSTX Comparison
Compare EYE & PSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYE
- PSTX
- Stock Information
- Founded
- EYE 1990
- PSTX 2014
- Country
- EYE United States
- PSTX United States
- Employees
- EYE N/A
- PSTX N/A
- Industry
- EYE Ophthalmic Goods
- PSTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EYE Health Care
- PSTX Health Care
- Exchange
- EYE Nasdaq
- PSTX Nasdaq
- Market Cap
- EYE 911.9M
- PSTX 909.4M
- IPO Year
- EYE 2017
- PSTX 2020
- Fundamental
- Price
- EYE $11.45
- PSTX $9.51
- Analyst Decision
- EYE Buy
- PSTX Hold
- Analyst Count
- EYE 3
- PSTX 3
- Target Price
- EYE $14.00
- PSTX $9.00
- AVG Volume (30 Days)
- EYE 1.4M
- PSTX 2.6M
- Earning Date
- EYE 11-06-2024
- PSTX 11-07-2024
- Dividend Yield
- EYE N/A
- PSTX N/A
- EPS Growth
- EYE N/A
- PSTX N/A
- EPS
- EYE N/A
- PSTX N/A
- Revenue
- EYE $2,177,092,000.00
- PSTX $150,858,000.00
- Revenue This Year
- EYE N/A
- PSTX $131.92
- Revenue Next Year
- EYE $2.80
- PSTX N/A
- P/E Ratio
- EYE N/A
- PSTX N/A
- Revenue Growth
- EYE 20.66
- PSTX 203.18
- 52 Week Low
- EYE $9.56
- PSTX $1.87
- 52 Week High
- EYE $24.11
- PSTX $9.58
- Technical
- Relative Strength Index (RSI)
- EYE 48.84
- PSTX 88.59
- Support Level
- EYE $11.23
- PSTX $9.35
- Resistance Level
- EYE $11.83
- PSTX $9.56
- Average True Range (ATR)
- EYE 0.52
- PSTX 0.08
- MACD
- EYE -0.07
- PSTX -0.09
- Stochastic Oscillator
- EYE 32.34
- PSTX 76.67
About EYE National Vision Holdings Inc.
National Vision Holdings Inc is an optical retailer in the U.S. Its product portfolio includes eyeglasses and sunglasses, contact lenses, accessories, and other products. The company has two operating segments; Owned and Host segment includes company-owned brands America's Best and Eyeglass World, In America's Best stores, vision care services are provided by optometrists or by independent professional corporations and Host operating consist of Military and Fred Meyer which provide eye exams by independent optometrists, and the Legacy segment manages the operations of, and supplies inventory and lab processing services to Legacy retail Vision Centers. It earns a majority of its revenue from the Owned and Host segment.
About PSTX Poseida Therapeutics Inc.
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.